Growing body of evidence about IRX‑2

News & Publications › Publications  


Clinical Data

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers

Gregory T Wolf, Jeffrey S Moyer, Michael J Kaplan, Jason G Newman, James E Egan, Neil L Berinstein, Theresa L Whiteside, et al., OncoTargets and Therapy, 2018:11 3731–3746

Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen

Neil L. Berinstein, Michael McNamara, Ariane Nguyen, James Egan & Gregory T. Wolf, et al. , OncoImmunology, DOI: 10.1080/2162402X.2017.1423173

A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.

Freeman SM, Barrera Franco JL, Kenady DE, et al. Am J Clin Oncol. 2011;34(2):173-178.

Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.

Wolf GT, Fee WE Jr, Dolan RW, et al. Head Neck. 2011;33(12):1666-1674.

A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.

Whiteside TL, Butterfield LH, Naylor PH, et al. Cancer Immunol Immunother. 2012;61(6):783-738.

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.

Berinstein NL, Wolf GT, Naylor PH, et al. Cancer Immunol Immunother. 2012;61(6):771-782.

Preclinical Data

IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.

Czystowska M, Han J, Szczepanski MJ, et al. Cell Death Differ. 2009;16(5):708-718.

Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic.

Czystowska M, Szczepanski MJ, Szajnik M, et al. Cancer Immunol Immunother. 2011;60(4):495-506.

IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro.

Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL. J Immunother. 2007;30(6):624-633.

IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells.

Schilling B, Harasymczuk M, Schuler P, Egan J, Ferrone S, Whiteside TL. PLoS One. 2013;8(2):e47234.

IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model.

Schilling B, Harasymczuk M, Schuler P, Egan JE, Whiteside TL. J Mol Med (Berl). 2012;90(2):139-147.

IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

Schilling B, Halstead ES, Schuler P, Harasymczuk M, Egan JE, Whiteside TL. Cancer Immunol Immunother. 2012;61(9):1395-1405.

IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.

Naylor PH, Hernandez KE, Nixon AE, et al. Vaccine. 2010;28(43):7054-7062.

Peptide based vaccine approaches for cancer—a novel approach using a WT-1 synthetic long peptide and the IRX-2 immunomodulatory regimen.

Naylor PH, Egan JE, Berinstein NL. Cancers (Basel). 2011;3(4):3991-4009.


Prognostic Value of Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma

Spector ME, Bellile E, Amlani L, et al. JAMA Otolaryngol Head Neck Surg. Published online September 05, 2019. doi:10.1001/jamaoto.2019.2427